GLP-1 Maintenance Visit Checklist: What to Bring, Track, Ask, and Leave With

By the WPG Research Team · Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. Last verified: August 12, 2026 · Next full review: November 2026 · How we built this checklist ↓

GLP-1 maintenance visit checklist: the short answer

This GLP-1 maintenance visit checklist is for adults already on a GLP-1 who are near their goal, at their goal, or on a steady long-term dose. Bring four things: your exact medicine and dose in milligrams, a 7-day log of weight, appetite, and side effects, your full medicine list, and any refill or insurance notices. Ask three questions: Is my dose a label-listed maintenance dose for my reason for taking it? What are we checking today, and why? What will my plan need at renewal? Leave with five things in writing.

What changes the answer: the FDA-approved label for your exact product lists different maintenance or ongoing doses, and your reason for taking it can narrow the list again. Your clinician still decides what is right for you. And if insurance pays, your plan may use a renewal test you will not see unless you ask for the actual criteria.

⚠️ This is not an urgent-care page. Severe or fast-worsening symptoms are not maintenance-visit questions. Bad stomach pain that won't quit, upper belly pain with yellow skin or fever, vomiting you can't stop, or trouble breathing or swallowing — use your care team's urgent instructions or get prompt care now. Don't wait for Tuesday.

Two things most people don't know walking in

1. Zepbound 7.5 mg and 12.5 mg are not listed as maintenance doses in the current FDA-approved label. The label lists 5 mg, 10 mg, and 15 mg for weight maintenance, and 10 mg or 15 mg for sleep apnea. Lilly also says it has not sponsored studies of tirzepatide at 7.5 mg or 12.5 mg as maintenance doses. If you have been kept at one of those strengths, that is a conversation to have — not a reason to panic, and not a reason to change anything on your own.

2. Wegovy 1.7 mg is a maintenance dose on the current label. For adult weight reduction and heart-risk reduction, the label lists 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended. So “get to 2.4 or come off” is not what the current label says.

Your visit in one table

Open my one-page visit sheet — copy it into Notes, print it, or fill it in on paper. It is on this page. There is no form or email gate.

One honest limit, up front

This page will not tell you the right dose for you, and it will not hand every reader the same lab list. That would look more helpful than it is. Your drug, your diagnosis, your symptoms, your other medicines, and your current goal decide which questions actually matter. Anyone who gives you one universal panel and one universal dose plan is guessing at your chart.

Here's the upside of that limit: because we're not your prescriber, we have no reason to nudge you toward a higher dose, a longer plan, or a bigger bill. What we can do is show you exactly what current FDA-approved labels say, what dated plan documents ask for, and what to walk out with — so the person who can answer gets the best use of a short visit instead of your vaguest one.

What people are actually worried about

“I'm approaching my goal weight and starting to think seriously about maintenance with my doctor.” — r/GLPGrad

“How do I convince my doctor to keep me on a maintenance dose?” — r/Zepbound

“I go to every appointment with written notes and questions.” — r/Zepbound

Patient language, not medical evidence. These show the worries people bring into maintenance appointments. One person's experience doesn't tell you what's right for you.

That second one is the quiet fear on this whole page: they're going to take it away. Let's deal with that directly, because the facts are kinder than the fear.

What is a GLP-1 maintenance visit actually for?

A GLP-1 maintenance visit is a follow-up after your dose has settled or you're near a long-term goal. Its job is to confirm the medicine is still helping, still tolerable, and still the right plan — and to set your dose, monitoring, contact rules, next date, and refill. It may also be the visit your program requires before the next refill.

The starting visit asked one question: should you take this at all? This visit asks a different one: should anything change?

That difference matters, because a lot of people show up to a maintenance visit still braced for the first one. They over-explain. They apologize for a plateau. They say "everything's fine" because fine sounds like the right answer.

"Everything's fine" is the least useful thing you can say in that room. It gives your clinician nothing to work with, and it's how people end up on autopilot for two years.

The five reasons you're probably here

1. A message landed in your portal: time for your follow-up before we can refill.
2. You hit your goal weight — or the scale stopped moving and you don't know if that's a win or a problem.
3. Your program moved you from monthly to quarterly check-ins and it felt like being dropped.
4. A renewal letter, or a prior authorization about to expire.
5. You want to ask for a lower dose and you're not sure you're allowed to.

If you're number five, skip ahead — that section is written for you.

You are almost certainly not behind

Here's a number nobody quotes, and it comes from inside the Wegovy label itself. In the big long-term heart-outcomes trial, of the people still on treatment at one year: 76% were on 2.4 mg, 8% were on 1.7 mg, and 16% were on lower doses. At two years it was 77%, 7%, and 17%.

Read that again. Roughly one in four people still taking Wegovy were below the recommended 2.4 mg dose. In a clinical trial. With study staff checking in.

So if you are on 1.7 mg instead of 2.4 mg, you are not the only long-term Wegovy patient below the recommended dose. That trial does not prove a lower dose is right for you, and it does not answer Zepbound dosing. It does show that real long-term treatment did not look like one dose for every person.

Long-term use is also more common than it was when Wegovy first launched. In a Prime Therapeutics claims analysis of 23,025 commercially insured adults without diabetes, 62.7% of people who started Wegovy in early 2024 were still persistent at 12 months, compared with 33.2% of those who started in 2021. The separate three-year cohort contained 5,780 people. Claims can miss cash-paid or compounded fills, and these results do not represent Medicare or Medicaid.

Who should leave this page

We'd rather send you somewhere useful than keep you here.

• Still choosing a first medicine or provider? This page assumes you already have one. Take the matching quiz instead.
• Trying to judge whether your telehealth program's follow-up is safe and complete? That's a different job — see what a complete GLP-1 telehealth follow-up should include.
• Shopping for a long-term maintenance program or provider? See our comparison of GLP-1 maintenance programs after weight loss. This page doesn't rank providers, on purpose.
• Having severe or fast-worsening symptoms right now? Stop reading. Use your care team's urgent instructions.

Is the dose you're on actually a maintenance dose?

Maybe not — and that is more common than most people realize. The first question is what the current FDA-approved label calls your dose for your exact product and reason for taking it. Zepbound's 7.5 mg and 12.5 mg strengths are part of the dose-escalation ladder but are not listed as maintenance doses. Wegovy's maintenance list depends on why it was prescribed.

This is the single most useful thing you can check before your visit. The information is spread across four prescribing labels, so we put the current language in one place.

The Maintenance Dose Map

Last verified against current U.S. prescribing information: August 12, 2026. “Label-listed” describes the FDA-approved label. It does not replace your clinician's judgment, and it does not tell you to change your dose.

Sources: current Wegovy prescribing information, revised 06/2026; Zepbound prescribing information, revised 04/2026; Mounjaro prescribing information, revised 04/2026; Foundayo prescribing information, revised 07/2026.

Four things fall out of that table that change real conversations.

Wegovy: your maintenance dose depends on why it was prescribed

Wegovy is approved for several reasons, and the maintenance language is not the same for every one.

If you take it for adult weight reduction or heart-risk reduction, 1.7 mg and 2.4 mg are both maintenance doses, with 2.4 mg recommended. If you take it for MASH with stage F2–F3 fibrosis, 2.4 mg is the recommended maintenance dose and 1.7 mg is the lower-dose fallback. The 7.2 mg maximum-dose option is only listed for adult weight reduction after at least four weeks at 2.4 mg and only when more weight reduction is clinically indicated.

So “what's the maintenance dose for Wegovy?” does not have one answer anymore. Know which reason your prescription was written for before you ask about changing it.

Zepbound: three label-listed maintenance doses, two in-between strengths

Zepbound comes in six strengths. For weight reduction, the label lists 5, 10, and 15 mg as maintenance doses. It says 2.5 mg starts treatment and is not approved as a maintenance dosage. The 7.5 mg and 12.5 mg strengths appear in the dose-escalation path but are not named in the maintenance-dose list.

Lilly's own medical information page addresses 7.5 mg and 12.5 mg directly and says the company has not sponsored studies of tirzepatide at those strengths as maintenance doses.

If you have been on 7.5 or 12.5 mg for months, that sentence does not prove your prescription is dangerous or wrong. But it is worth asking: is there a reason we're here, and is a label-listed maintenance dose a better long-term place for me?

And note the sleep-apnea line. If Zepbound was prescribed for obstructive sleep apnea, only 10 and 15 mg are label-listed maintenance doses. Five milligrams counts for weight maintenance and does not count as a listed sleep-apnea maintenance dose. Same drug, same strength, different indication.

Same active ingredient, two labels: why Mounjaro and Zepbound use different dose language

Mounjaro and Zepbound both contain tirzepatide and come in the same six dose strengths. They are approved for different uses, and their labels use different dose language.

Mounjaro's label does not publish a separate maintenance-dose list. It says to move from 2.5 mg to 5 mg after four weeks, then raise the dose in 2.5 mg steps after at least four weeks when more glucose control is needed, up to 15 mg in adults. Zepbound's label names three maintenance doses for weight and leaves 7.5 and 12.5 mg off that list.

So the FDA-label answer to “is 7.5 mg a maintenance dose?” depends on which product and indication you mean. The clinical answer still depends on you, your response, and your prescriber.

Foundayo: a dose ladder without one named maintenance dose

Foundayo (orforglipron) is a once-daily pill approved in 2026. Its dose ladder works differently. You start at 0.8 mg, move to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 more.

From there, the label says the dose may be increased to 9, 14.5, or 17.2 mg after at least 30 days at the current dose, based on response and tolerability.

That means the label does not crown one “real” maintenance dose after 5.5 mg. It gives a response-based ladder. If someone told you that every person must reach 17.2 mg, that is not how the label is written.

If you're on an in-between strength

Do this, in this order:

1. Don't change anything yourself. Not the amount, not the timing, not the interval.
2. Bring the row. Print or screenshot the line from the table above for your drug and your reason for taking it.
3. Ask the neutral version of the question: “I'm on 12.5 mg. I read that the Zepbound label lists 10 and 15 mg as the maintenance doses for weight. Is there a reason we're at 12.5 mg, and is one of the listed doses a better long-term spot for me?”

That question gets a real answer. “Am I on the wrong dose?” gets a reassurance.

One more honest note. Some people genuinely want a rung that does not exist — a dose lower than the lowest one made. We've read people describe cutting or transferring medicine themselves to get there. We're not going to explain how, and you shouldn't do it. Dose changes belong with a prescriber, and the strength you draw is exactly where dosing errors happen. If the ladder doesn't have a step you want, that's a conversation, not a kitchen project.

→ My GLP-1 maintenance visit sheet

Copy this into Notes, print it, or fill it in on paper. It is here on the page — no form and no email gate.

Leave with these five lines filled in:

• Exact medicine, dose, and schedule: ____________________
• What to track, and what change matters: ____________________
• Which symptoms need a call or faster care: ____________________
• Next follow-up and any lab or eye-check date: ____________________
• Who owns the refill and coverage work: ____________________

What should you bring to your GLP-1 maintenance visit?

Bring the facts your clinician would otherwise spend your visit hunting for. That means your exact medicine and dose in milligrams, your full medicine list, any recent results, and any refill or insurance notice. A photo of your label beats memory every time.

Your visit may be short. Every minute spent reconstructing your own history is a minute not spent on your plan.

If you use a compounded medicine, bring this exact card

Compounded medicines are prepared by a pharmacy rather than approved by the FDA as a finished drug product. They are not FDA-approved products, which means the FDA does not review them before marketing for safety, effectiveness, or quality the way it reviews an approved product. Their concentrations and instructions can also vary, which creates a specific and well-documented risk at maintenance: the numbers can change on you.

The FDA has flagged dosing errors tied to compounded GLP-1s, including mix-ups where patients converted milligrams to syringe units incorrectly. In one set of reports, patients told to draw "5 units" — which was meant to be 0.05 mL — drew 50 units, or 0.5 mL. That's a ten-fold overdose. The agency has also noted that a single compounder may offer more than one concentration.

So bring all of this:

• Pharmacy name
• Concentration on the vial
• Your dose in milligrams
• The volume or units you draw
• Syringe size
• A photo of the current label
• A photo of the old label, if anything changed

Then ask one question, word for word: "Can you confirm my dose in both milligrams and the exact syringe units?"

If your vial, concentration, syringe, or written instructions changed since last time and nobody walked you through it, do not guess. Contact the prescriber or pharmacy before the next uncertain dose.

What should you track for 7 days before the visit?

You don't need a perfect diary. Seven honest days of trend beats one weight and one memory of a bad Tuesday. Track weight direction, hunger and food noise, side effects, whether eating and drinking got harder, energy, and any missed doses.

Here's the page. Screenshot it or print it.

The 0–10 scales are ours, built for this checklist to make a conversation easier. They are not validated medical scores.

A few notes on filling it in.

Weight direction, not one number. Same scale, same time of day, similar clothes. What matters is whether the line is flat, drifting up, or still going down. We're not giving you a target — that's between you and your clinician, and a number from a website has no business in it.

Food noise counts as data. If the intrusive food thoughts came back on days 5, 6, and 7 of your dose week and quieted down after your shot, say exactly that. That pattern is useful context. “I've been hungrier” is not.

Side effects need dates and duration. Not "some nausea." Try: "Nausea Tuesday and Wednesday, moderate, about 6 hours each, still ate normally."

Missed or late doses go in. All of them. Which brings us to the one nobody tells you to track.

Track your resting heart rate — because a video visit cannot measure it unless you bring it

This is one of the most overlooked items on a maintenance checklist, and it is in the label.

The Wegovy prescribing information tells clinicians to monitor heart rate at regular intervals. It also tells them to discontinue Wegovy if a sustained increase in resting heart rate is found. That is an instruction for the prescriber after evaluation — not a reason to stop the medicine on your own because of one watch reading.

The numbers behind that: in adult weight-reduction trials, average resting heart rate went up 1 to 4 beats per minute versus placebo. More people on Wegovy than placebo had a maximum jump of 20 beats per minute or more at a visit — 26% versus 16%. In the long heart-outcomes trial, the two-year average change was 3.8 beats per minute on Wegovy versus 0.7 on placebo. Mounjaro's label reports an average rise of 2 to 4 beats per minute versus 1 with placebo.

Now think about how a maintenance visit often happens: a video call, or a form in an app. A video call cannot measure your pulse unless you supply a reading.

So take it yourself if your clinician has not told you otherwise. Sit quietly for five minutes, then count your pulse for 60 seconds, or read it from a device you already use. Do it on three mornings out of the seven. Write the numbers down. If you have older readings from an office visit, bring those too so there is a before.

That is a two-minute task that gives your clinician a data point the Wegovy label asks for and a remote visit may not collect.

→ Print the 7-day tracking page — blank grid plus the pulse instructions, ready for the fridge.

What should you ask about your maintenance dose?

Don't just ask "should I lower my dose?" Ask what this dose is meant to do now, what would justify a change, and what would change it back. And don't change the amount or the timing on your own — the label rules above only apply to the schedule you were actually prescribed.

Five questions. Write the answers in the room.

Can I ask to go down to a lower dose?

Yes. It's a normal request, not a confession.

Several labels give more than one ongoing option or tell the clinician to consider response and tolerability. Wegovy lists 1.7 mg and 2.4 mg as maintenance doses for adult weight and heart-risk uses. Zepbound lists 5, 10, and 15 mg for weight maintenance and says to consider a lower maintenance dose when a current maintenance dose is not tolerated. Foundayo reaches 5.5 mg, then says the dose may rise based on response and tolerability; it does not name one required maintenance dose.

And remember the 76/8/16 numbers from earlier: about a quarter of Wegovy patients still on treatment at one year in the heart-outcomes trial were below the recommended 2.4 mg dose. You would not be the first person to want less medicine.

There is also new randomized evidence for one specific lower-dose path. In the 2026 SURMOUNT-MAINTAIN trial, 378 adults who had lost at least 5% and tolerated tirzepatide 10 or 15 mg were randomized to stay at their maximum tolerated dose, reduce to 5 mg, or switch to placebo. At week 112, total weight change from the original baseline averaged −21.9%, −16.6%, and −9.9%, respectively. A 5 mg reduction preserved more of the earlier loss than stopping, but it did not perform as well as staying at 10 or 15 mg. That is evidence for a clinician-directed 5 mg path after high-dose tirzepatide — not a universal taper plan.

Reasons people ask to go down that are worth saying out loud:

• Side effects that never fully settled
• Cost, when the exact cash price changes with dose
• They hit their goal and don't want to keep losing
• They want the smallest dose that holds the result

One verified public account put the problem plainly: “I've stayed on 2.5 for my whole Zepbound journey… Since I use the pens I can't lower my dose at all.”

One person's public account. Not a typical result, and not medical evidence. We're including it because it is the exact position many maintenance patients are in: wanting a smaller step than the product makes.

The timing question almost nobody asks

If insurance pays for your medicine, here is a question that can prevent a coverage surprise: “Does changing my dose today affect what the renewal form asks?”

It can. One dated CareFirst/CVS Caremark Zepbound form asks whether the patient has completed at least three months at a stable maintenance dose. A change does not automatically mean your coverage resets, but it may change how the prescriber answers that exact form.

That doesn't mean don't change your dose. It means the dose conversation and the coverage conversation belong in the same visit, and the order can matter. Full renewal details are below.

About stretching doses to every other week

You'll see this discussed as a maintenance strategy — taking a weekly shot every 10 days, or every two weeks. Some articles present it as a way to lower your effective dose or your cost.

Be careful with it, and ask a specific question: “Is that the labeled schedule for my exact product, or a clinician-directed off-label plan? What's the reason, and how will we check that it's working?”

Stretching an interval is not the same thing as lowering a dose. It changes how much drug is in your body over time in a way the weekly labels do not describe. That may still be a reasonable clinical choice for you. It is not a reasonable choice to make from a blog post.

What labs should you ask about — and four things not to ask for

There's no single GLP-1 lab panel for everyone, and no reason to request every test at every visit. What fits depends on whether you have diabetes, what symptoms you've had, your other conditions, and whether your dose changed. Ask what's being monitored in your case and when.

Most checklists online hand you one big panel. That's the easy version to write and the wrong version to follow. It leads to tests you don't need and, worse, it buries the two or three that actually matter for you.

Do I need bloodwork at every visit?

Not necessarily. Some people need regular condition-specific monitoring. Others need a test because something new showed up. The question isn't "what's the GLP-1 panel?" It's "what are we watching in my case, and how often?"

If your lipase comes back high, read this before you panic

Here's a number that saves people a bad weekend, and it's straight out of the labels.

On Wegovy, average amylase went up 15% to 16% and average lipase went up 39% compared to baseline. Those are pancreatic enzymes. On Mounjaro, average amylase went up 33% to 38% and lipase 31% to 42%.

The Wegovy label then says the clinical meaning of a raised lipase or amylase is unknown when there are no other signs or symptoms of pancreatitis.

So: average enzyme levels rose in these trials. A flagged number with no symptoms is not automatically pancreatitis. In the Wegovy MASH trial, lipase above three times the upper limit showed up in 4.7% of people on Wegovy versus 1.3% on placebo.

If your result is flagged, the useful question is not "do I have pancreatitis?" It's "is this the expected rise on this medicine, or is something else going on?"

Four things not to ask for

Being the page that tells you what to skip is more useful than being the page that tells you to demand everything.

1. A routine thyroid ultrasound or calcitonin blood test. The Wegovy label is unusually direct here: routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection, and such monitoring may increase the risk of unnecessary procedures because of low test specificity and a high background rate of thyroid disease. A lump in your neck, trouble swallowing, or lasting hoarseness is a different situation and should be checked. But don't request the screen as a maintenance ritual.

2. Pancreatic enzymes "just to be safe." See above. Without symptoms, you're likely to get a number you can't interpret.

3. Every test on a list you found online. Including ours. The table above is a menu of conversations, not a requisition form.

4. A number to hit. Not from us, not from a chart. Ask your clinician what result would change your plan. That's the number that matters, and it's yours.

→ Use the lab-question table for your situation — start with the row that matches your diabetes status, symptoms, or recent change. Bring the question, not a demand for every test.

What symptoms and life changes should you mention?

Bring more than weight and nausea. New medicines, low blood sugar, vision changes, pregnancy plans, birth control, a surgery on the calendar, or a changed compounded vial can all change the plan. Some of these should not wait for a routine visit.

We've sorted these three ways so you're not guessing about urgency.

Four of these deserve more than a table row.

Pregnancy planning has a two-month lead time

If pregnancy is anywhere in your plans, this belongs on your list today — not next year.

The Wegovy label says to stop the drug at least two months before a planned pregnancy, because semaglutide stays in your system a long time. Its own pharmacology section says the drug will be present in circulation for about five to seven weeks after your last dose. Zepbound's label directs stopping when a pregnancy is recognized.

That's a real timeline. If you're thinking about trying in the spring, the conversation is now.

Birth control: two drugs, two different clocks

This one catches people mid-titration, and the two clocks are not the same.

Two drugs. Two labels. Two windows. And both reset every time you go up a dose — which is exactly the thing you might be discussing at this visit.

If you take the pill and you're about to titrate, ask before you leave the room.

Surgery and sedation: tell all three teams

Don't decide this from a generic article — including this one.

The current labels tell patients to inform their care teams before any planned surgery or procedure, because these drugs slow how fast the stomach empties. The Wegovy label also says available data are not enough to say whether pausing the drug reduces the risk of stomach contents going into the lungs during anesthesia.

Multi-society guidance published by anesthesiology groups in October 2024 takes a middle path: many lower-risk patients can continue the medicine, while people at higher risk of delayed stomach emptying may need an individual plan.

So the question is not "do I stop?" It's "what plan have my prescriber, my surgeon, and my anesthesia team agreed on?" Tell all three. Get it in writing.

Bones: the long-term item nobody mentions

Here is a long-term signal from the label that rarely appears on maintenance-visit checklists.

In the long heart-outcomes trial, where people were on Wegovy for a median of about 37 months, there were more hip and pelvis fractures on the drug than on placebo among female patients: 1% versus 0.2%. Among patients aged 75 and older, it was 2.4% versus 0.6%. The liver-disease trial reported fractures in 4.4% on the drug versus 3.3% on placebo.

Those are small numbers. They came from long-duration trials — the kind of evidence that matters more once treatment lasts for years.

We're not telling you to demand a bone scan. We're telling you that if you're a woman, or over 75, or both, "should we talk about bone health?" is a fair maintenance question with label data behind it.

If you're thinking about the 7.2 mg Wegovy dose

One number to bring into that decision: odd skin sensations — burning, tingling, sensitive skin — showed up in 22% of people on 7.2 mg, compared with 6% on 2.4 mg and 0.3% on placebo.

Of the people who had it, 23% had their dose reduced. And of 38 people who recovered and then went back up to 7.2 mg, 17 — nearly half — had it come back.

That's worth knowing before you go up, not after.

How often should GLP-1 maintenance visits happen?

Follow-up is usually closer when treatment starts or changes and can spread out when things are steady. The 2026 ADA Standards say that after an obesity medicine is started, effectiveness and safety should be checked at least monthly for the first three months and at least quarterly after that.

That is an initiation baseline, not a legal minimum and not one schedule for every long-term patient. Symptoms, diabetes, other medicines, dose changes, pregnancy plans, procedures, and coverage rules can all move the next visit sooner.

What “stable” should still include, even at quarterly visits:

• A written goal for this stretch
• A check on whether the medicine is still helping and still tolerable
• An up-to-date medicine list
• A next date, or a clear condition for scheduling one
• A refill plan
• A route to reach a clinician sooner if something changes

If your check-in has none of those, it is a refill, not a follow-up. We deal with that below.

Your A1C schedule is a separate question. If you have diabetes, the visit calendar and A1C calendar do not have to match. ADA patient guidance says A1C is usually checked every six months when the last result was in range, and every three months when medicines changed or the last result was not in range. Ask for both dates.

The scheduling trick: work backward from your renewal

Here is a practical move that costs nothing.

If insurance pays and your authorization has an end date, do not schedule the next visit by feel. Schedule it far enough before the renewal date that there is time to submit paperwork and fix anything missing.

Published plan documents vary. One CareFirst/CVS form asks about three months at a stable maintenance dose. Other policies ask for a dated baseline weight, a current weight, a specific percentage, or proof that symptoms improved. If your renewal is in November and the visit is in late October, you may not have room to find an old baseline or correct a missing note.

Ask: “When does my authorization end, which exact document controls my renewal, and when should we meet so the paperwork has room?”

What will your insurance need at renewal?

If a plan pays for your GLP-1, renewal may turn on a dated weight, a treatment-response note, how long you have been on therapy, or whether the benefit is covered at all. The numbers do not match from one document to the next. Your own benefit document, authorization letter, and current criteria control — not the insurer logo on your card and not this table.

This is the half of maintenance nobody connects to the visit. We pulled the examples below from the plans' own published documents and named each one so a reader does not mistake one form for a universal rule.

Last verified: August 12, 2026.

Four things in that table are worth saying plainly.

The FDA label and the payer form answer different questions. Zepbound 7.5 mg and 12.5 mg are not in the FDA label's maintenance-dose list. Yet the cited Highmark policy accepts those requested strengths for coverage. A payer accepting a dose does not rewrite the FDA label, and the FDA label does not tell you whether your plan will pay.

Your baseline may mean “before any GLP-1,” not “before this brand.” Cigna's policy says to use the baseline before any GLP-1 or GLP-1/GIP obesity drug. If you switched from Wegovy to Zepbound, the old starting weight may matter more than the weight on switch day.

A stable-dose question is not a universal restart rule. The CareFirst/CVS form asks about three months at a stable maintenance dose. That does not prove every dose change restarts every authorization. It means you should ask how your prescriber will answer the exact form before the renewal is due.

The benefit document can overrule the policy page. Cigna says a customer's benefit plan document controls when it conflicts with the published policy, and it notes that many plans exclude weight-loss medicines. That is why the right first question is not “What does Cigna require?” It is “Which document controls my renewal?”

Bring the notice. Bring the date. Ask: “Who submits this, when, which exact criteria are being used, and what do you need from me?” Then write the name down.

For the paperwork process and denial fixes, see our Wegovy prior-authorization guide and our guide to GLP-1 providers that handle prior authorization.

The five things to leave with in writing

A good maintenance visit ends with more than "keep doing what you're doing." Leave with your exact dose and schedule, what to track, which symptoms need a call, when the next check happens, and who owns your refill. Ask for it in your after-visit summary so it's not living in your memory.

This is the whole point of the appointment. Everything above just gets you here.

The five-point check

Don't leave until you can tick all five.

• I know my exact medicine, dose in milligrams, and schedule — plus what not to change without calling.
• I know what to track and which change matters — a specific trend or number, not "keep an eye on it."
• I know which symptoms need a call, and which need faster care than a call.
• I know when my next follow-up is, and when my next labs or eye check are due.
• I know who owns my refill and my coverage steps, by name.

Who owns what

That last one is where most plans quietly fall apart. Ask directly, and write down a name or a role for each:

• Who writes the prescription
• Who responds to side effects between visits
• Who orders and reviews labs
• Who handles diabetes care, if that's separate
• Who handles the refill
• Who handles prior authorization and renewal
• Who to reach urgently, and how
• Whether records get shared with your primary care doctor

"The team" is not an answer. If nobody owns your renewal, nobody submits it.

One sentence to ask before you hang up: "Can you put the dose, the monitoring plan, and my next follow-up date in my after-visit summary?"

→ Fill in the five-point written plan — print it, save it to your phone, or paste the five lines into a portal message.

What if your maintenance plan isn't working?

"Not working" covers five different problems: you're still losing when you don't want to, hunger and food noise came back, weight is creeping up, side effects now outweigh the benefit, or cost is breaking the plan. Bring the trend and ask for a clear rule about what would change the plan — don't change the medicine yourself.

If you're still losing and you don't want to be

This is a real problem and people are shy about raising it, because "still losing weight" sounds like winning.

Bring: your weight direction, whether you're skipping meals because you have no appetite, your energy, your strength, and any dizziness. Then ask: "What would tell us that continued loss has become a problem for me?"

You want a threshold, not a shrug.

If hunger or food noise is coming back

Bring the pattern, not the feeling. When in your dose week does it hit? Is your weight actually moving, or just your appetite? Did you miss or delay a dose? Did sleep, stress, or another medicine change?

Ask: "Does this trend change the plan now, or should we watch it longer, and for how long?"

If you're thinking about stopping

Here is what randomized withdrawal evidence says, and it is more useful than the headline.

Switching to placebo led to regain on average. In STEP 4, after a 20-week semaglutide run-in, people who switched to placebo gained 6.9% from the switch point over the next 48 weeks, while people who stayed on semaglutide lost another 7.9%. In SURMOUNT-4, from the switch point to week 88, people who continued tirzepatide lost another 5.5% while the placebo group gained 14.0%. By the end, 89.5% of people who continued had kept at least 80% of their earlier loss, compared with 16.6% of those who stopped.

The amount regained tracked with how much of the health improvement reversed. A follow-up analysis of 308 SURMOUNT-4 participants who stopped tirzepatide grouped people by the share of lost weight they regained. In the group that regained less than 25%, waist size, non-HDL cholesterol, and fasting insulin showed little or no clear change, but blood pressure and A1C still rose. Larger regain groups had larger reversals across more measures. The group that regained at least 75% moved many cardiometabolic measures back toward baseline.

Translation, in plain terms: maintenance is not pass-fail, but regain is not neutral either. A small drift did not reverse every measured gain. More regain reversed more of them. That is a more honest frame than “hold every pound or lose everything.”

Lower-dose maintenance now has one strong tirzepatide trial. SURMOUNT-MAINTAIN found that reducing from a tolerated 10 or 15 mg dose to 5 mg preserved more weight reduction than stopping, though less than staying at the higher dose. This supports one clinician-directed lower-dose path. It does not tell every person how or when to reduce.

Switching from an injection to a daily pill also has randomized evidence. In the 2026 ATTAIN-MAINTAIN trial, adults who had lost weight on injectable tirzepatide or semaglutide were randomized to oral orforglipron or placebo. The orforglipron groups kept more of the earlier loss over 52 weeks than placebo. That is evidence from a specific study population, not a rule that every injection user should switch.

And here is the honest gap that remains. These are maintenance trials, not universal taper-to-zero protocols. They do not validate homemade dose spacing, pen splitting, or one step-down schedule for every drug and every person.

So if anyone hands you a confident calendar for coming off, ask where it came from. The truthful answer may be that it is clinical judgment. That can still be good care. It just should not be dressed up as a published universal protocol.

What if your provider just approves the refill?

A refill can be part of a real follow-up, but it shouldn't replace a clear dose, monitoring, and contact plan. Send your checklist before the visit, and ask who is responsible for your labs, your side effects, your records, and your next review. Bringing an agenda gives a refill-only visit a better chance to become a real follow-up.

Send this before your appointment

Copy, paste, edit, send through your portal a day or two ahead:

"I'm preparing for my maintenance visit. Here's my current medicine and dose, my last dose change date, a 7-day log of weight, appetite and side effects, and my refill timeline. I'd like to leave with a written dose plan, what to monitor, what should prompt a call, my next follow-up date, and who owns my refill and renewal. Thank you."

Two things happen when you send that. Your clinician walks in prepared. And you've made the agenda before anyone else set one.

Refill-only versus a real maintenance visit

Signs the care model may not fit you

Stated plainly, without drama:

• No way to reach a clinician about an important symptom
• You can't name your prescriber
• Your dose isn't documented anywhere you can see
• Nobody accepts responsibility for follow-up
• Repeated, unexplained changes to your formulation or concentration
• You asked for a written plan directly and didn't get one

One of those is a bad week. Several of those, repeatedly, is a structural problem — and it's not one you can fix by being a better patient.

If cost or coverage is what's breaking your plan

If your coverage is ending or the price stopped working, that is an access problem, not a treatment failure — and it has different solutions. Ask what happens during a gap, ask whether a covered FDA-approved option fits you, and get your records before you change anything. Do not let a gap happen quietly.

Say it out loud at your visit. Clinicians cannot route around a cost problem they do not know about.

Ask these four:

1. If my coverage ends, what's the plan for the gap?
2. Is there a covered FDA-approved option that is appropriate for me?
3. What records do I need if I have to move somewhere else?
4. Who submits the appeal, and by when?

One thing to be clear about: compounded and FDA-approved products are not interchangeable. Compounded medicines are prepared by a pharmacy and are not FDA-approved, which means the FDA has not reviewed the finished product before marketing for safety, effectiveness, or quality. Everything in the Maintenance Dose Map on this page comes from FDA-approved labels. If you switch between an approved and compounded product, the instructions, concentration, and numbers on the vial may change. Ask before the next uncertain dose, not after.

If you need an FDA-approved route while you sort out coverage

For a reader who needs an answer about brand coverage while a renewal or appeal is pending, Ro's free insurance checker is a practical first step. Ro says the checker contacts the insurer and reports coverage details for the Ozempic pen, Wegovy pen, and Zepbound pen. It does not submit a treatment request or write a prescription.

Ro Body pricing, verified August 12, 2026: $39 for the first month, then as low as $74/month with an annual plan paid up front, or $149/month on the ongoing monthly plan. Medication is billed separately.

The honest limit: the free checker does not check Zepbound KwikPen, Foundayo tablets, or Wegovy tablets. It also cannot make a plan approve treatment. Ro says it offers cash-pay FDA-approved options when insurance does not cover them, but the exact medicine price depends on the product and dose.

Start Ro's free GLP-1 coverage check — use it to get a current report, then bring that report to the clinician handling your prescription.

If your current program adjusts your dose, orders the checks you need, and answers your messages — stay where you are. Switching costs you continuity and history for no benefit. Go fill in your visit sheet instead. That is the higher-value move for you.

And if you are genuinely shopping for a long-term maintenance path rather than solving a gap, see our GLP-1 maintenance program comparison. That is the right page for that decision, not this one.

Advertising disclosure: we may earn a commission if you start care through some links on this page. It never changes what we verify or what we recommend.

How we built and checked this page

We built this as a patient organization tool, not a treatment protocol. The medical items come from current FDA-approved prescribing information, published clinical studies, and dated plan criteria. The Bring, Track, Ask, and Leave With workflow, the Maintenance Dose Map, the plan-document comparison, the visit sheet, and the five-point check are our own editorial work.

What we actually verified — August 12, 2026

• Current U.S. prescribing information for Wegovy, revised 06/2026, including maintenance dosage by indication, the 7.2 mg option, heart-rate monitoring, fracture and enzyme data, pregnancy timing, and thyroid-monitoring language
• Current U.S. prescribing information for Zepbound, revised 04/2026, including its label-listed maintenance doses, sleep-apnea dosing, and oral-contraception window
• Current U.S. prescribing information for Mounjaro, revised 04/2026, for the same-active-ingredient comparison
• Current Foundayo prescribing information, revised 07/2026, including its escalation ladder, drug-interaction cap, and contraception window
• Lilly's published medical information answer about 7.5 mg and 12.5 mg not being studied by Lilly as maintenance doses
• Published continuation or reauthorization documents from CareFirst/CVS Caremark, Cigna, UnitedHealthcare, and Highmark, with the exact document named in the table
• STEP 4, SURMOUNT-4, the 2025 SURMOUNT-4 regain analysis, SURMOUNT-MAINTAIN, and ATTAIN-MAINTAIN
• FDA alerts on dosing errors with compounded semaglutide
• 2026 ADA obesity-medication follow-up guidance and ADA patient guidance on A1C timing
• Multi-society perioperative guidance on GLP-1 medicines and anesthesia
• Prime Therapeutics' persistence analysis, including the difference between its 23,025-person one-year cohorts and 5,780-person three-year cohort
• Ro's live pricing and coverage-checker pages
• Existing pages on this site, to keep this page focused on visit preparation instead of repeating the provider-comparison pages

What we did not verify

• What dose is right for you
• Whether any specific test is medically necessary for you
• Your plan's exact rules — plans customize them, documents change, and your benefit contract may override a public policy
• Your state's prescribing rules
• Your prescriber's response times or protocols
• Whether the trial results above apply to your body, diagnosis, or treatment history
• Whether a switch, reduction, pause, or stop is appropriate for you

What we chose not to publish

• Any method for splitting or transferring doses. We've read the workarounds. Publishing them would be a bad trade.
• Any universal step-down, spacing, or taper-to-zero schedule. New maintenance trials now support specific studied paths, but they do not create one schedule for every patient and product.
• Any weight target, calorie number, or protein target. Those depend on your body and your clinician, and a generic number on a maintenance page does more harm than good.

Frequently asked questions

What is a GLP-1 maintenance visit?

It's a follow-up after your dose has settled or you're near a long-term goal. The visit should review whether the medicine still helps, whether it's still tolerable, what to monitor, and what your dose, contact, follow-up, and refill plan is going forward. It may also be the visit your program requires before the next refill.

Do I need bloodwork at every GLP-1 visit?

Not everyone needs the same tests at every visit. It depends on whether you have diabetes, what symptoms you've had, your kidney risk, your other conditions, and whether your dose changed. Ask what's being monitored in your case and when it's due, rather than requesting a standard panel.

How often should I see my doctor while taking a GLP-1?

Follow-up is normally closer when treatment starts or changes. The 2026 ADA Standards say that after an obesity medicine is started, effectiveness and safety should be checked at least monthly for the first three months and at least quarterly after that. Your long-term schedule may need to be sooner depending on symptoms, diabetes, other medicines, dose changes, or plan requirements.

Should I lower my dose when I reach my goal weight?

There is no single answer for every person or medicine. Wegovy lists 1.7 mg and 2.4 mg as maintenance doses for adult weight and heart-risk uses. Zepbound lists 5, 10, and 15 mg for weight maintenance and says to consider a lower maintenance dose if the current maintenance dose is not tolerated. A 2026 tirzepatide trial also found that a clinician-directed reduction from 10 or 15 mg to 5 mg preserved more prior loss than stopping. Ask what the goal is now and what would justify a change. Do not change the amount or timing on your own.

Is 7.5 mg or 12.5 mg of Zepbound a maintenance dose?

They are not listed as maintenance doses in the current Zepbound label. The label lists 5 mg, 10 mg, and 15 mg for weight maintenance, and 10 mg or 15 mg for sleep apnea. Lilly says it has not sponsored studies of tirzepatide at 7.5 mg or 12.5 mg as maintenance doses. If you have been on one long term, it is worth asking why — not worth panicking about or changing it on your own.

Can I take my weekly GLP-1 every other week for maintenance?

Stretching the interval is not the same as lowering the dose, and it isn't the labeled schedule for these products. If it's being suggested, ask whether it's a labeled schedule for your exact product or a clinician-directed off-label plan, what the reasoning is, and how it will be monitored.

What should I bring if I use a compounded medicine?

Bring a clear photo of the label, the pharmacy name, the concentration, your dose in milligrams, the syringe size, the units you draw, and both the old and new instructions if anything changed. The FDA has reported dosing errors involving different concentrations and milligram-to-unit conversion, so confirming both numbers out loud is worth the 30 seconds.

Do I need to stop my GLP-1 before surgery?

Don't decide from a general rule. Tell your prescriber, your surgeon, and your anesthesia team. Current labels instruct patients to inform their care teams before planned procedures, and multi-society guidance says many lower-risk patients can continue while people at higher risk of delayed stomach emptying may need an individual plan.

Does tirzepatide affect oral birth control?

Zepbound's labeling advises people using oral hormonal contraception to switch to a non-oral method or add a barrier method for four weeks after starting and four weeks after each dose increase. Foundayo's label uses a 30-day window after starting and after each dose escalation. Both reset when your dose goes up, so raise it before you titrate.

Do I need a thyroid blood test or ultrasound?

Not as a routine GLP-1 maintenance step. The Wegovy label says routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection and may lead to unnecessary procedures. A neck lump, trouble swallowing, or lasting hoarseness is a different situation and should be evaluated.

What if I'm still losing weight after reaching my goal?

Bring a trend covering weight direction, appetite, whether you're eating regular meals, energy, and strength. Then ask what result would tell your clinician that continued loss has become a problem, and what should prompt an earlier call. Don't reduce the dose on your own.

What if my insurance stops covering my GLP-1?

Bring the denial or renewal notice, how many doses you have left, the authorization end date, and any pharmacy messages. Ask who owns the next step, which exact criteria document is being used, what records are needed, and what the plan is during a gap. Public policies differ sharply, and your own benefit document may control.

What are the five things I should leave with?

Your exact medicine and dose, what to track and what change matters, which symptoms need a call, when your next follow-up or lab check is, and who owns your refill and coverage steps. Ask for those in your after-visit summary so you're not relying on memory.

One last thing

Maintenance isn't a test of willpower. It's the part where you and your care team decide what keeps the result safe and workable — and that's a decision you're allowed to have opinions in.

Bring one page. Leave with one plan. That's the whole job.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Sources

1. Wegovy (semaglutide) injection and tablets, U.S. Prescribing Information, revised 06/2026. Novo Nordisk.
2. Zepbound (tirzepatide) injection, U.S. Prescribing Information, revised 04/2026. Eli Lilly.
3. Mounjaro (tirzepatide) injection, U.S. Prescribing Information, revised 04/2026. Eli Lilly.
4. Foundayo (orforglipron) tablets, U.S. Prescribing Information, revised 07/2026. U.S. Food and Drug Administration.
5. Eli Lilly Medical Information: why Zepbound 7.5 mg and 12.5 mg are not included as maintenance doses.
6. FDA alert on dosing errors associated with compounded injectable semaglutide.
7. CareFirst/CVS Caremark Zepbound prior-authorization form 6192-C, dated 12/26/2025.
8. Cigna Drug Coverage Policy IP0206, effective 06/01/2026.
9. UnitedHealthcare commercial program 2026 P 1114-21, effective 07/01/2026.
10. Highmark Enhanced formulary policy J-1388-014.
11. Wilding JPH et al. STEP 4 randomized withdrawal trial. JAMA. 2021.
12. Aronne LJ et al. SURMOUNT-4 randomized clinical trial. JAMA. 2024.
13. Horn DB et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal. JAMA Internal Medicine. Published online November 24, 2025.
14. Horn DB et al. SURMOUNT-MAINTAIN. The Lancet. 2026.
15. Orforglipron for maintenance of body-weight reduction: ATTAIN-MAINTAIN. Nature Medicine. 2026.
16. ADA Standards of Care in Diabetes—2026, Section 8: Obesity and Weight Management.
17. American Diabetes Association: Health Checks for People With Diabetes.
18. Multi-society clinical practice guidance for GLP-1 medicines before surgery. American Society of Anesthesiologists, October 2024.
19. Prime Therapeutics: GLP-1 therapy for obesity among members without diabetes—three-year persistence and one-year trend analysis.
20. Ro Weight Loss Program pricing, accessed August 12, 2026.
21. Ro GLP-1 Insurance Coverage Checker, accessed August 12, 2026.
22. Patient-language examples: GLPGrad maintenance discussion, Zepbound maintenance-dose concern, appointment-note discussion, and 2.5 mg maintenance account. These are patient experiences, not medical evidence.